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Introduction: Up to 50% of acute pulmonary exacerbations in children with cystic
ﬁbrosis (CF) can be caused by viral infections but the role of respiratory viruses in
exacerbations in adult patients has not been as well deﬁned. A recent study in our
Adult CF Unit using ten years of viral serology data found the annual incidence
of admissions per patient associated with viral infection was 4.9%. This study
analyses the utility of viral immunoﬂuorescence (IF) and shell vial culture (SVC)
for diagnosing acute viral infections in adults with CF.
Methods: Nasopharyngeal swabs were obtained from adult CF patients presenting
with an acute exacerbation between October 2005 and October 2007 and sent for
viral IF & SVC. Sample were analysed for the presence of inﬂuenza A & B,
parainﬂuenza 1, 2 & 3, adenovirus, and respiratory syncytitial virus (RSV).
Results: Nasopharyngeal swabs were obtained from 244 adult patient episodes
during the study period. Only one (0.4%) was positive by IF (for RSV). Conversely,
in the same period, three (7.9%) of 38 paediatric patient episodes were positive (two
RSV, one inﬂuenza A).
Conclusions: Viral IF & SVC yielded fewer positives in adults with CF than our
historical serology results. It was not clear if this was due to lower sensitivity of
viral IF & SVC compared to viral serology, sample bias or because there was a
true reduction in cases. However, we have now replaced viral IF & SVC with viral
PCR in our CF units.
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The chronical infection with Pseudomonas aeruginosa (PSA) is a key event in the
clinical course of patients with cystic ﬁbrosis (CF). A daily tobramycin inhalation
leads to the eradication of the ﬁrst detected PSA to about 80%.
The purpose of the study it is to examine, how long the patients remain free of
PSA after the coming off the early therapy.
We followed retrospectively 26 patients (age: (mean±SD) 6.9±3.5 years; Sex: male
14, female 12) where PSA was proved for the ﬁrst time, for a period of at least 3
up to 8 years. 26 patients inhaled tobramycin (80mg twice daily; for 12 months) as
early PSA eradication therapy. 12/26 got additional sporadic systemic antibiotics.
During treatment PSA disappeared (i.e. 3 negative swabs in a sequence with a
least distance of 30 days) in all 26 patients. 11/26 remained without a new PSA
proof for (mean±SD) 1962±688 days. In 15/26 PSA was detected again during the
follow-up period. 6/15 patients were tested PSA positive under the initial therapy,
9/15 after the end of therapy. The recurrence of PSA after stopping initial therapy
was either early (<300 days; n = 5) or late (>500 days; n = 4). In four patients PSA
isotypes were tested for the ﬁrst and the new proof. In 2 patients with an early
PSA recurrence the same PSA isotypes were detected. In 2 patients with late PSA
recurrence different isotypes were identiﬁed. Our results conﬁrm the success of the
early PSA treatment. However they also point to the fact that the disappearance
of PSA under the early PSA therapy represents a temporary suppression and not a
complete eradication in a relevant part of the patients.
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Introduction: Early eradication therapy is an effective strategy for delaying the
onset of chronic Pseudomonas infection. The aims of this study were to observe
whether antibody levels herald early infection and to assess the relevance of prior
clinical status, pseudomonas antibody levels and choice of antibiotic regimen on
success rates.
Methods: Prospective 2 year study in adult patients. Eradication therapy was 1
month Azithromycin plus three months Ciproﬂoxacin and a nebulised antibiotic.
Patients with a concurrent respiratory exacerbation received an additional 14 days
of intravenous antibiotics. Success was deﬁned as 3 negative respiratory cultures
over a six month period.
Results: 59 new acquisitions of P. aeruginosa; 8 classiﬁed as ‘never’, 34 as ‘free’
and 7 as ‘intermittent’. Antibody levels were normal (8U/ml) at time of isolate in
63%. No patient with a ﬁrst ever P. aeruginosa infection had a raised antibody level
at the start of treatment. P. aeruginosa was successfully eradicated in 71% of cases.
There was no signiﬁcant difference in the success rate according to prior clinical
status, antibody level at the start of therapy or antibiotic regimen used. There was
a greater failure rate in patients with high antibody levels who received nebulised
and oral therapy compared to those who also received intravenous treatment (42%
vs. 22%, p = 0.04). Pseudomonas antibody levels did not change signiﬁcantly in
those in whom eradication was successful.
Conclusion: Antibodies to Pseudomonas do not reliably herald a new infection or
predict the likelihood of successful or failed eradication. The addition of intravenous
therapy may improve the success rate in those with elevated antibodies.
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Colonisation of 235 (120 males) Cystic Fibrosis pts (mean age 10.5 yrs range 1−30)
negative for Pseudomonas aeruginosa (Pa) was monitored by means of regular
sputum culture every three months, during four consecutive years; ELISA tests
were performed to detect serum IgG and IgA against Pa lipopolysaccaride at the
beginning of the study and then once a year.
Serology data in a subgroup of 46 pts (22 males mean age 10.5 yrs range 2−24)
showing culture conversion during the follow-up period of one year before T − 1
and one year after T + 1 the ﬁrst infection, were compared.
Serum antibody level (mean + SD) of IgG and IgA are shown in the table. IgG levels
at T + 1 were signiﬁcantly higher when compared to T − 1. At T − 1 the IgG and
IgA levels were above the cut-off in 13 (28%) pts and in 12 (26%) pts respectively.
In contrast at T + 1 IgG were positive in 25 pts (54%) whereas IgA only in 10
pts (22%). In 30 of the 235 pts, who remained with negative culture all over the
follow-up period, serum levels of IgG were above the cut-off (mean 11.7U.I./ml,
range 6.5−19.6).
Conclusions: The number of pts positive at serology compared to culture may
indicate culture identiﬁcation failures because of lower bacteria densities in the
airways in ﬁrst or occasional infection, although a higher diagnostic value of
serology cannot be excluded. Antibodies may be markers of previous infections
occurred several months or years before. CF pts with positive serological tests and
negative culture should be monitored closely.
IgG (cut off: 6U.I./ml) IgA (cut off: 8U.I./ml)
T − 1 T+ 1 T− 1 T+ 1
mean/SD 4.18±3.49 9.69±7.03 3.89±8.55 11.69±22.7
p(T + 1 vs T − 1) 0.000025 0.1056
